Posts Tagged ‘prostate cancer’

Prostate Cancer: Statistics That May Surprise You

prostate cancer factsAccording to American Cancer Society (ACS), the cancers that most frequently affect men are prostate, colon, lung, and skin cancers. The most common men’s specific cancer in America, affecting 1 in 7 men, is prostate cancer. One new case occurs every 2.3 minutes and a man dies from prostate cancer every 18 minutes.

You probably didn’t know this shocking statistic, from the Prostate Cancer Foundation; a man is 35% more likely to be diagnosed with prostate cancer than a woman is to be diagnosed with breast cancer.

Yet, despite these realities we don’t talk as openly as women do about a serious health condition. There are disputes about screenings for prostate cancer specifically, but I am an advocate of screening– including not only the PSA but also the digital rectal exam. From the screenings, you and your doctor will determine if biopsies are needed to detect aggressive cancers that need immediate treatment but also pick up cancers that are “quasi cancer” and safe to watch rather than treat immediately. Over a five-to-10-year period, about a third of men whose cancers are considered low risk turn worse and require treatment. When prostate cancer is caught in the early stages the treatment options and outcomes are significantly better.

Nearly 3 million American men currently living with prostate cancer, Emory Healthcare is committed to providing the highest quality health care to its patients, with the most up-to-date treatment options available. A multidisciplinary prostate cancer team — involving urology medical oncology, radiation oncology, diagnostic imaging– at Saint Joseph’s Hospital and Emory’s Winship Cancer Institute have come together to move novel treatments for advanced prostate cancer forward.

Start today and take control of your wellness.

  • Honestly discuss prostate cancer.
  • Avoid cancer-causing activities like tobacco use and excessive drinking.
  • Be proactive. Commit yourself to regular physical activity to maintain a healthy weight.
  • Know your risks and your family history.
  • Get regular check-ups; speak with your primary care physician about whether prostate screening is appropriate for you.

If you do not have one, find a primary physician through our Emory Healthcare Network or call Health Connection at 404-778-7777 to learn more from a registered nurse.


About Dr. Sanda

Martin G. Sanda, MD is chair of the Department of Urology at Emory University School of Medicine and Director of the Prostate Cancer Center at Emory’s Winship Cancer Institute.

As a urological surgeon specializing in cancers of the prostate and bladder, Sanda focuses on developing new surgical and non-surgical approaches to cancer care and to improving the quality of life among cancer survivors. Currently, he is spearheading studies that seek to develop urine tests for detecting prostate cancer; develop benchmarks for improving quality of life among cancer survivors; and develop innovative prostate cancer vaccines.

Cancer Clinical Study Leads to Video Tool for Prostate Cancer Patients
Two Patients Benefit from Two Alternative Treatment Options for Prostate Cancer
PSA Screening for Prostate Cancer – A Healthy Debate
Questions on Validity of PSA Test as Prostate Cancer Screening Tool
Prostate Cancer, To Screen or Not?
Winship Cancer Institute Website

Foods that Fight Prostate Cancer

prostate healthy eatingEating a healthy diet helps reduce your chances of getting cancer, but which foods should men eat to reduce their prostate cancer risks and why? See our list of cancer-fighting foods below to find out.

1. Tomatoes

Tomatoes are packed with lycopene; a member of the carotenoid family found commonly in red pigmented fruit and vegetables, lycopene has been established as having strong antioxidant properties. Research suggests that lycopene is a preventive agent for prostate disease. [1]

2. Watermelon

Watermelon, like tomatoes, is loaded with lycopene. In fact, one cup has the lycopene content of two tomatoes. But watermelon is also rich in vitamin C and beta-carotene, antioxidants that help to protect cells from damage and rid your body of harmful cells that can lead to cancer.

3. Garlic

Garlic is famed for its supposed health benefits, and studies concerning its anti-cancer benefits look promising. Several compounds are involved in garlic’s possible anticancer effects – garlic contains allyl sulfur and other compounds that slow or prevent the growth of tumor cells. In one study published in the Journal of the National Cancer Institute in 2002, scientists discovered that men who ate about a clove of garlic daily had a 50 percent reduced risk of developing prostate cancer. [2]

4. Green tea

Green tea contains polyphenol compounds, particularly catechins, which are antioxidants and whose biological activities may be relevant to cancer prevention. Studies have shown that green tea and its components effectively mitigate cellular damage due to oxidative stress, and green tea extract is reported to induce cancer cell death and starve tumors by curbing the growth of new blood vessels that feed them. [3]

5. Soy

Soy fills the body with isoflavones — compounds that act like the hormone estrogen in humans — and have been found to have an abundance of anti-cancer benefits. Studies have shown that the isoflavones in soy inhibit prostate cancer cell growth, induce cellular death, and enhance the ability of radiation to kill prostate cancer cells. [4]

6. Beans

Beans are a good source of protein a good alternative to meat. Beans are high in fiber

7. Broccoli

Studies suggest a link between cruciferous vegetables and prostate cancer risk.A member of the cruciferous vegetables and contains phytochemical sulforaphane that targets cancer cells.

8. Fish

Have a healthier balance of Omega-3 and omega 6 fatty acids may help prevent the development of prostate cancer. Eat fish found in cold waters to increase omega-3 intake. Salmon, Herring, Mackerel, Trout, Sardines.

[1] Ilic D., “Lycopene for the prevention and treatment of prostate disease.”
[2] Milner JA. “A historical perspective on garlic and cancer.” J Nutr. 2001 Mar;131(3s):1027S-31S.
[3] Butt MS, Sultant MT. “Green tea: nature’s defense against malignancies.”
[4] Mahmoud AM, Yang W, Bosland MC., Soy isoflavones and prostate cancer: A review of molecular mechanisms.


About Tiffany Barrett

tiffanybarrettTiffany Barrett, MS, RD, CSO, LD, is a Certified Specialist in Oncology Nutrition and sought after expert in her field. She is a key contributor to support programs at Winship and provides personalized nutritional advice to Winship Cancer Institute patients who are undergoing cancer treatment. She also consults with patients who have completed treatment and wish to continue to build a strong and healthy diet. She earned her Bachelor of Science at Florida State University and a Master of Science at University of North Florida. Tiffany is a Certified Specialist in Oncology Nutrition and completed a Certificate of Training in Adult Weight Management.

Cancer Clinical Study Leads to Video Tool for Prostate Cancer Patients
Two Patients Benefit from Two Alternative Treatment Options for Prostate Cancer
PSA Screening for Prostate Cancer – A Healthy Debate
Questions on Validity of PSA Test as Prostate Cancer Screening Tool
Prostate Cancer, To Screen or Not?

Prostate Cancer: Risk Factors, Screenings, Symptoms & Therapy Live Chat on November 24th

prostate-chatAccording to the American Cancer Society (ACS), about 1 man in 7 will be diagnosed with prostate cancer during his lifetime. If detected early and depending on the type and stage of the disease, prostate cancer can be treated.

Join John G. Pattaras, MD and Peter Rossi, MD, two physicians with Winship Cancer Institute of Emory University’s prostate cancer team, on Tuesday, November 24th at 12pm EST for a live chat where they will answer your questions about prostate cancer risk factors, screenings, symptoms and therapy. All are welcome to attend an online open-forum discussion about prostate cancer with Dr. Pattaras and Dr. Rossi. Sign up for this live chat here.

Chat Sign Up

Prostate Cancer: Is Active Surveillance an Option?

guys (1)For many years, most men with prostate cancer were given the option of either surgery or radiation. Over time, doctors saw many men had prostate cancer that was less aggressive and unlikely to spread to other parts of the body or shorten lifespan. Doctors were also learning that many of these men were experiencing the downsides of prostate cancer treatment (e.g. difficulty with erections, leakage of urine) without benefit.

In response to “over treatment”, some centers offered men with low-risk prostate cancer prognosis were enrolled in a clinical trial of “active surveillance”. After 15 years of follow-up, half of the patients were able to avoid prostate cancer treatment. Today, these studies—with nearly 20 years follow-up—show excellent results of active surveillance for low-risk prostate cancer.

Men with low prostate-specific antigen (PSA) test results, low-grade tumors, and minimal abnormalities on the prostate exam are considered for the newer protocols. Active surveillance programs usually involve repeat biopsies every one to two years and PSA tests every three to six months. Treatment is recommended if the patient is found to have higher-risk disease.

It is difficult to hear a cancer diagnosis and then be presented with surveillance as an option to avoid treatment. Yet, cancer patients can trust that active surveillance is a process that can delay or avoid cancer treatment side effects with rare risk of death from prostate cancer. Newer technologies, like multiparametric magnetic-resonance imaging and molecular biomarkers, may identify more prostate cancer patients who would benefit from active surveillance.

In the end, among selected patients on active surveillance, death or progression of cancer is rare. There is no evidence that prostate cancer patients who undergo delayed prostate cancer treatment fare worse than those treated immediately. In fact, they avoid the side effects of cancer treatment over that time. If newly diagnosed with prostate cancer, active surveillance may be an option worth discussing with your urologist or radiation oncologist.

Additional Resource:
The Prostate Cancer Support Group meets the 1st Wednesday of every month from 11:00 AM – 12:30 PM at the Clifton Campus. If you’re interested in further details visit:

Cancer Clinical Study Leads to Video Tool for Prostate Cancer Patients
Two Patients Benefit from Two Alternative Treatment Options for Prostate Cancer
PSA Screening for Prostate Cancer – A Healthy Debate
Questions on Validity of PSA Test as Prostate Cancer Screening Tool
Prostate Cancer, To Screen or Not?
Winship’s Approach to Prostate Cancer Treatment

About Dr. Filson

filsonChristopher Filson, MD, MS, is an assistant professor of urology at Emory University School of Medicine. Dr. Filson started practicing with Emory Healthcare in July 2015. His main clinical specialties include robotic surgery, laparoscopic surgery, cystectomy, urinary diversion, prostatectomy and nephrectomy. Dr. Filson received his Medical Degree from University of Michigan in Ann Arbor MI. His postdoctoral training included a surgery internship and urology residency also at University of Michigan and a Fellowship in Urologic Oncology at University of California Los Angeles.

Navigating a Prostate Cancer Diagnosis

Prostate cancer is the most common cancer among men and can often be treated successfully. In fact, more than 2 million men in the U.S. are prostate cancer survivors. But a daunting set of questions faces the more than 200,000 men who are newly diagnosed with prostate cancer each year: is prompt or aggressive treatment necessary, or is “watchful waiting” an option? And if choosing treatment, then what kind?

Hugh Smith was diagnosed with prostate cancer at the age of 51. Knowing that members of his family had died from prostate cancer prompted Smith to get checked. When tests showed the presence of cancer, he looked for an experienced prostate specialist who could provide the most advanced treatment available. Winship’s Dr. Martin Sanda performed a prostatectomy via robotic surgery at Emory Saint Joseph’s Hospital in 2013. Since then, Smith says he’s had no side effects and no recurrent cancer. He thanks God and the expertise of his cancer team for the good results. Now he wants to encourage other men to take charge of their own health. “Some men would rather not know about their risk of prostate cancer, but I say go in with your eyes wide open.”

Winship is at the forefront of research aimed at helping men at all stages of their journey with prostate cancer. A crucial segment of that journey starts with determining if a cancer is aggressive and fast-growing, or the type of slow, indolent cancer that could be safely monitored without treatment.

Winship urologists and cancer biologists are part of a nationwide effort to develop new blood and urine tests that could substantially improve detecting prostate cancer and determining how aggressive individual cancers might be. To more read about our approach to prostate cancer and other research advances in detecting and treating prostate cancer, go to

Cancer Clinical Study Leads to Video Tool for Prostate Cancer Patients
Two Patients Benefit from Two Alternative Treatment Options for Prostate Cancer
PSA Screening for Prostate Cancer – A Healthy Debate
Questions on Validity of PSA Test as Prostate Cancer Screening Tool
Prostate Cancer, To Screen or Not?
Winship’s Approach to Prostate Cancer Treatment

winshiprostateblog1 banner

A New Method to Find the Site of Returning Prostate Cancer

prostate cancer diagram

The yellow arrow and the white arrows on the pictures above indicate areas of prostate cancer that were invisible to previously available imaging techniques. Instead, they were detected using a new positron-emission tomography (PET) test called FACBC, which was developed and is being tested at Emory University.

A voluntary research study is being conducted to help men with recurring prostate cancer by using advanced imaging technology called FACBC to guide radiotherapy and determine the best possible course of treatment. This study would be added as an extra layer in your ongoing cancer treatment.*

We are looking for patients to participate in this clinical trial.

“By participating in this study, patients may have the opportunity to have an FACBC scan. The precision of this type of scan could help guide more effective treatment for patients whose cancer has returned,” says Ashesh Jani, MD, radiation oncologist and principal investigator.

Have you previously had surgery to treat prostate cancer, but think the cancer has returned? Has your doctor recommended radiation therapy as the next step in your care?

Participants must meet specific eligibility criteria:
• You are over 18 years of age.
• You had surgery (prostatectomy) to treat your prostate cancer.
• Your doctor suspects that the cancer has returned (as indicated by a rising PSA).
• Radiation therapy is now being considered as the next step in your care.

The trial is open at these locations: Winship Cancer Institute on the Clifton Road campus, Winship at Emory University Hospital Midtown, Winship at Emory Saint Joseph’s Hospital and Georgia Cancer Center for Excellence at Grady.

*You will be followed for a minimum of three years, with PSA levels checked every six months, in addition to having study-related lab work. There is no cost for the FACBC scan or the Food & Drug Administration (FDA) required lab work. All other imaging, lab work, biopsies (if any), radiation therapy and any other therapy will be billed to your insurance provider or paid out of pocket by you. You may be eligible for a travel voucher if you are chosen to undergo the FACBC scan.

For more information or to enroll, contact Ashesh Jani, MD, at (404) 778-3827 or

Learn more about Winship’s approach to Prostate Cancer Treatment
Read Winship’s Brochure on FACBC

winshiprostateblog1 banner


Recurrent Prostate Cancer: Where is it?

Tiffany Dunphy and Van Jackson, radiation therapists at Winship at Emory Saint Joseph's Hospital, work with prostate cancer patients undergoing radiation treatment.

Tiffany Dunphy and Van Jackson, radiation therapists at Winship at Emory Saint Joseph’s Hospital, work with prostate cancer patients undergoing radiation treatment.

“It’s a lot easier to plan the attack, if we know where the enemy is,” says Winship urologist Peter Nieh, MD. “If a cancer is still localized, we may want to try salvage therapy, either radiation or surgery, before advancing to something systemic.”

Depending on how primary treatment took place, a prostate cancer often comes back in the prostate bed (where the prostate gland was), and may appear in nearby lymph nodes. In advanced cases, the cancer may spread to the bones.

Emory radiologist and Winship member David Schuster, MD and radiochemist and Winship member Mark Goodman, PhD have been developing a PET (positron emission tomography) imaging probe that shows considerable potential for detecting recurrent prostate cancer.

Usually in PET imaging, radioactive glucose is injected into the body, and since cancer cells have a sweet tooth, they take up a lot of the radioactive tracer. But the tracer also appears in the urine, complicating prostate cancer detection efforts since the prostate is so close to the bladder. In contrast, the probe 18F-FACBC, based on amino acids, is taken up by prostate cancer cells but doesn’t appear as much in urine.

FACBC has its limitations. It also may be taken up in benign prostate hyperplasia or inflammation. This means it probably won’t be as useful by itself for evaluating primary prostate cancers, but it has a lengthening track record in recurrent cancer.

In a 2011 publication, Schuster and his colleagues compared FACBC to ProstaScint, a commercially available probe. FACBC showed superior sensitivity and specificity in detecting tumors outside the prostate bed. Schuster is now collaborating with Winship radiation oncologist Ashesh Jani, MD to study FACBC’s benefits in designing radiation treatments for patients with recurrent prostate cancer after prostatectomy.

In Jani’s clinical trial study for recurrent prostate cancer, which lasts until 2017, one group of patients is examined using FACBC, while another gets conventional imaging. The question is whether using information gleaned from FACBC to direct the radiation results in a longer lasting remission than with the control group.

Marble countertop salesman Paul Reckamp, who was a participant in Jani’s study, keeps a file on his phone noting his PSA levels for the last several years. Reckamp had a radical prostatectomy in July 2010 at Emory Saint Joseph’s Hospital, but the cancer appeared to come back a year and a half later. FACBC imaging confirmed that the cancer had appeared in nearby lymph nodes but not elsewhere, and doctors could then plan radiation treatment that drove his PSA levels back down again.

“I couldn’t have been more pleased with the study,” he says. “It told me and the doctors what we wanted to know.”

As a National Cancer Institute (NCI) designated cancer center, Winship Cancer Institute of Emory University’s participation in clinical trials ensures our prostate patients have access to progressive resources and technology. For men with recurrent prostate cancer, there are newer methods of imaging such as magnetic resonance imaging (MRI) and positron emission tomography (PET). 

winshiprostateblog1 banner


New Tests to Improve Decision Making in Prostate Cancer Treatment

This blog was originally posted June 3, 2015 AACR Press Office.

Prostate Cancer Cells

Prostate Cancer Cells

A diagnosis of prostate cancer can often result in difficult choices for both patients and physicians. Prostate cancer is the most common non-skin cancer diagnosed in American men, with over 200,000 diagnosed cases and almost 28,000 deaths per year. A major reason why prostate cancer is diagnosed so frequently is that the FDA-approved blood test for prostate-specific antigen (PSA) is widely used and is highly sensitive. However, the PSA test cannot distinguish prostate cancers that are aggressive from indolent cases that will not spread if left untreated.

It has been estimated that about 50 percent of men who are diagnosed with prostate cancer as a result of PSA testing would remain asymptomatic if left untreated. Furthermore, the side effects of surgery or radiation therapy can be significant, and include urinary incontinence and sexual dysfunction. These side effects from overtreatment without clear survival benefit led the U.S. Preventive Services Task Force (USPSTF) to recommend against PSA screening. As a result, there is a pressing clinical need for new prostate cancer biomarkers that can discriminate aggressive from indolent disease to prevent overtreatment of indolent cases and undertreatment of aggressive cases. This is one example of how precision medicine can both improve cancer care and reduce overall health care expenditures.

While single biomarkers can be useful, quite often using a panel of many genes is more robust, predictive, and informative than a single biomarker such as PSA. Moreover, RNA is generally much easier to detect and quantitate than protein, even at low amounts, and RNA-based assays can test many targets simultaneously. RNA-based approaches to prostate cancer biomarker discovery include the analysis of which genes are switched on and off in a cancer cell, as well as measurement of previously unappreciated RNAs that do not code for proteins, and detection of known genetic mutations.

Biopsies themselves carry some risk of infection, discomfort, and expense. Consequently, less invasive biomarkers that can use blood or urine samples are more desirable, and likely to be adopted more broadly, resulting in better patient compliance and follow up. Many researchers are thus looking for prostate cancer biomarkers that can be readily measured from biofluid specimens.

There are several different clinical questions that new biofluid biomarkers for prostate cancer could potentially address. First, if I have a high PSA, do I really need a biopsy? Second, if my biopsy looks indolent, am I a good candidate for active surveillance, or do I really need surgery or radiation? And third, if I do need surgery or radiation, will it be curative, or should I think about enrolling in clinical trials? These are all important questions that many scientists and physicians are currently pursuing in their biomarker research.

Recent research in our lab has identified a gene panel that can predict whether a patient is likely to have a recurrence after surgery, and we are currently working on determining if this panel can also identify good candidates for active surveillance. This research is using advanced sequencing technologies on both urine and biopsy samples, and could make it easier for patients and their doctors to safely decide that surgery or radiation are unnecessary, reducing side effects and unnecessary treatments. A number of other commercially available panels are already in use including Prolaris, Oncotype Dx, and Decipher, though none are currently FDA approved. Hopefully, with additional research to determine the best biomarkers of cancer aggressiveness and approval of such tests, patients and physicians can be confident in the treatment decisions that they make, leading to the best possible health outcomes.

About Dr. Moreno

carolos moreno, phdCarlos S. Moreno, PhD, is an associate professor in the Departments of Pathology & Laboratory Medicine, and Biomedical Informatics at the Emory University School of Medicine. He is a member of the Cancer Genetics and Epigenetics research program at Winship Cancer Institute. Moreno specializes in cancer bioinformatics and systems biology, cancer genomics, cancer biomarkers, and transcriptional networks. He is the informatics project leader for the Emory Molecular Interaction Center for Functional genomics (MicFG) as part of the Cancer Target Discovery and Development (CTD²) Network to identify protein-protein interaction networks.

Moreno has been a member of the American Association for Cancer Research since 2003 and received an AACR Minority Scholar Award in 2006.

Related Resources

Cancer Clinical Study Leads to Video Tool for Prostate Cancer Patients

At Emory, research plays a key role in the mission to serve our patients and their families. Medical advances and improvements to patient care have been made possible by research and volunteer participation in clinical trials. More than 1,000 clinical trials are offered at Emory, making a difference in people’s lives, today.

Recently, a clinical study initiated by Winship Cancer Institute of Emory University, found that providing prostate cancer patients with a video-based education tool significantly improved their understanding of key terms necessary to making decisions about their treatment.

The breakthrough study was led by three Winship at Emory investigators; Viraj Master, MD, PhD, FACS; Ashesh Jani, MD; and Michael Goodman, MD, MPH; and is the feature cover story of this month’s Cancer, the peer-reviewed journal of the American Cancer Society.

In 2013, Master, Jani and Goodman released an Emory study that showed that prostate cancer patients (treated at Grady Hospital in Atlanta) experienced a severe lack of understanding of prostate key terms. The original study showed only 15 percent of the patients understood the meaning of “incontinence”; less than a third understood “urinary function” and “bowel habits”; and fewer than 50 percent understood the word “impotence.”

In response to their findings, the three principle investigators jumped to find a solution to the problem. The latest study explored using a video-based tool to educate prostate cancer patients on key terminology. The physicians predicted that with a better understanding of terms linked to disease, patients would be able to participate in shared and informed decision-making throughout the prostate cancer treatment process.

About the Prostate Cancer Video Trial:

  • 56 male patients were recruited from two low-income safety net clinics and received a key term comprehension test before and after viewing the educational video.
  • The video software (viewed by participants on iPads) featured narrated animations depicting 26 terms that doctors and medical staff frequently use in talking with prostate cancer patients.
  • Learn more by watching this video:

clinical trials for prostate cancer

Results of the Prostate Cancer Video Trial:

Participants who viewed the educational video demonstrated statistically significant improvements in comprehension of prostate terminology. For instance, before viewing the application, 14 percent of the men understood “incontinence”; afterward, 50 percent of them demonstrated understanding of the term.

“This shows that video tools can help patients understand these critical prostate health terms in a meaningful way. The ultimate goal is to give patients a vocabulary toolkit to further enable them to make shared and informed decisions about their treatment options,” says Viraj Master. “Our next goal is to improve the tool further, and study this tool at different centers.”

Learn more about clinical trials at Emory >>

Find a clinical trial at Emory >>


Additional Information about the Prostate Cancer Trial:

The research for this study was made possible by a Winship Cancer Institute multi-investigator pilot grant and the contributions of faculty and students from Winship, the Rollins School of Public Health and the Emory School of Medicine.

This study was led by three Winship at Emory investigators: Viraj Master, MD, PhD, FACS, Winship urologist and director of clinical research in the Department of Urology at Emory University; Ashesh Jani, MD, professor of radiation oncology in the Emory School of Medicine; and Michael Goodman, MD, MPH, associate professor of epidemiology with the Rollins School of Public Health.

Related Resources:

Takeaways from Dr. Sanda’s Chat on Prostate Cancer

Thank you for attending the live chat with Dr. Martin Sanda on prostate cancer. (Link to: ) Your questions and participation were terrific. Below are additional Q&As that we didn’t have time to get to during the live chat portion.

As you know, prostate cancer is the second most common cancer in men, second only to skin cancers. Emory Healthcare is privileged to partner with you in your health and is ready and able to assist if needed. Please use the resources on this page and this website to contact us if we can help in any way.

Question: What are today’s best prostate cancer diagnosis methodologies?
Answer: Despite a lot of advances in imaging tests such as MRI or higher-resolution ultrasound, there is still a need to biopsy the prostate in order to determine whether or not prostate cancer is present. The biopsy provides important information, not only as to whether there are cancer cells, but if so, how aggressive or how fast-growing those cancer cells appear to be. Bone scans and CT scans are useful to look for spread of prostate cancer elsewhere. Also, new PET (positron emission tomography) scans or other diagnostic studies that image molecules which are taken up by cancerous tissue and not by normal tissue are emerging. But, their role in standard care is not yet sorted out. MRI can provide valuable information about the size and configuration of tumors in the prostate itself and the immediate vicinity, as part of a watchful waiting monitoring plan, or as a guide for treatment planning.

Question: What are the dangers of conventional biopsy?
Answer: The main risk of prostate cancer biopsy is infection, which can be seen in approximately one out of 50 to one out of 100 cases and can require hospitalization for treatment. More commonly, some men may feel faint after a biopsy and should plan on taking the day off or taking it easy if they undergo a prostate biopsy procedure. Rarely, men might experience bleeding from where the needle is inserted into the prostate and this, too, can require hospitalization. Common after prostate biopsy is having blood in the semen or ejaculate; however, this does not pose any danger or risks and will typically resolve in a matter of a few weeks.

Question: Are there new drugs and and prostate cancer treatments on the near horizon?
Answer: Major scientific discoveries have taken place over the past five to 10 years and many more are underway. This has led to a half-dozen new treatments for advanced prostate cancer that have become available in the past several years. A broad range of new treatments are being developed, including more refined types of hormonal therapy, including immune therapies or therapeutic vaccines and also targeted therapies that are aimed at molecular differences between the cancer cell and normal tissue.

Related Resources:

About Dr. Martin Sanda

Dr. Martin SandaMartin G. Sanda, MD, an internationally recognized prostate cancer surgeon and scientist, was appointed chair of the Department of Urology at Emory University School of Medicine and service chief for Emory Healthcare. He also serves as director of the Prostate Cancer Center, which will be established within Emory’s Winship Cancer Institute.

Sanda joins Emory from Harvard Medical School, where he was professor of surgery in urology, and from Beth Israel Deaconess Medical Center, where he served as director of the Prostate Cancer Center. He was also the co-leader of the Prostate Cancer Program at the Dana Farber Cancer Center.